• Corpus ID: 31389896

Biphenabid (Probucol): a new hypocholesterolemic agent.

@article{Kalams1971BiphenabidA,
  title={Biphenabid (Probucol): a new hypocholesterolemic agent.},
  author={Z Kalams and Michael P. Dacquisto and Glenn Kornett},
  journal={Current therapeutic research, clinical and experimental},
  year={1971},
  volume={13 11},
  pages={
          692-4
        }
}
11 Citations

Probucol: A Review of its Pharmacological Properties and Therapeutic Use in Patients with Hypercholesterolaemia

The mechanism of probucol’s cholesterol-lowering activity has not been clearly demonstrated, but some authors have suggested that inhibition of lipoprotein formation and/or impaired intestinal mucosal transport of cholesterol may be involved.

Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidemic agents probucol, clofibrate, and fenofibrate.

It was concluded that the hypocholesterolemic response elicited by probucol treatment does not involve significant changes in rat liver cell morphology and, ultrastructurally, no peroxisomal changes.

Drug management of hypercholesterolemia.

  • B. Martz
  • Medicine
    American heart journal
  • 1979

Probucol (Lorelco) in treatment of hyperlipemia.

Although probucol has no consistent effect on elevated triglyceride levels, it may be useful as an adjunct to other drugs that lower these concentrations in patients with types IIb, III, and IV hyperlipoproteinemia when hypercholesterolemia persists.

Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.

Probucol is useful as an adjunct to diet in lowering plasma cholesterol levels in patients with familial hypercholesterolemia, and was well tolerated by all patients.

Safety and Efficacy of Probucol During One Year of Administration

  • D. Nash
  • Medicine, Biology
    Journal of clinical pharmacology
  • 1974
Probucol produced a significant decrease in the serum cholesterol levels in patients with familial hypercholesterolemia and the confirmation of the hypocholesterolemic activity in the human was confirmed.